Transaction Overview

Strides Pharma Science Limited announced a strategic investment by a consortium led by Ascent Capital, along with co-investor Vintage Classic, in its wholly owned subsidiary Pivot Path Private Limited.

Financial Terms

  • Transaction values Pivot Path at approximately ₹2,300 million on a post-money basis
  • Strides will realize approximately ₹1,000 million from the transaction
  • Strides will retain approximately 20% ownership stake in Pivot Path
  • Includes primary capital infusion of ₹500 million to accelerate Pivot Path's growth and technology investments

Strategic Rationale

The transaction reflects Strides' strategy of creating, scaling and unlocking value from high-potential businesses while retaining participation in their future growth. It strengthens the Company's balance sheet and provides growth capital for Pivot Path to pursue its expansion strategy.

Background of Pivot Path

Pivot Path originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC), where it developed capabilities across:

  • Life sciences consulting
  • Digital transformation
  • Quality and compliance
  • Technology-enabled operational services

The business evolved into an independent platform serving industry-leading customers as demand from external pharmaceutical and life sciences companies grew. The business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the Hon'ble National Company Law Tribunal (NCLT) in May 2026.

Post-Transaction Status

Following completion of the transaction, Pivot Path shall be reclassified as an Associate of the Company.

Valuation Basis

The transaction has been undertaken based on an independent valuation conducted by a SEBI-registered merchant banker, reflecting the strength of Pivot Path's differentiated capabilities, established customer relationships and long-term growth potential.

Financial Performance

Pivot Path has established a profitable operating platform serving specialised, high-value segments within the life sciences industry. For FY26, the carved-out business reported:

  • Revenue: ₹1,447 million (including revenues for services rendered to Strides)
  • EBITDA: ₹169 million

Management Commentary

Badree Komandur, MD & Group CEO of Strides:

  • "Pivot Path exemplifies Strides' proven capability to identify, incubate and scale high-potential businesses"
  • "We have built a platform with specialised capabilities, a growing customer base and a strong foundation for future growth"
  • "This transaction unlocks value for Strides, provides Pivot Path with the resources to scale independently, and allows Strides to retain meaningful participation in its future success"

Raja Kumar, Managing Director & Founder of Ascent Capital:

  • "Pivot Path brings deep domain expertise across the core, non-discretionary segments of the pharmaceutical industry"
  • "Exceptionally well positioned to combine the power of technology and Agentic-AI with its 400+ subject matter experts"
  • Focus on building purpose-built solutions for global customers to manage compliance, digital transformation, and drug safety requirements

Business Description

Pivot Path Private Limited is a technology-enabled life sciences and manufacturing solutions company, offering:

  • Consulting services
  • Digital innovation
  • Operational services

The company focuses on delivering domain-driven solutions supported by advanced technologies, including AI and analytics, to address complex challenges in the pharmaceutical and manufacturing sectors.

About Ascent Capital

Ascent Capital is an India-focused private equity firm with over 175+ years of collective experience, partnering with high-growth companies across sectors such as technology and healthcare. The firm follows an entrepreneur-centric investment approach.

Board Meeting Details

The Board Meeting commenced at 15:00 hrs IST and concluded at 15:50 hrs IST on June 27, 2026.